Login to Your Account



Oxford BioTherapeutics Inks Target Validation Pact with BI

By Cormac Sheridan
Staff Writer

Tuesday, April 30, 2013
Oxford BioTherapeutics (OBT) Ltd. entered a target validation deal with Boehringer Ingelheim GmbH that will offer near-term revenues, with the added prospect of long-term development milestones and product royalties.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription